{"id":"NCT01573910","sponsor":"Alcon Research","briefTitle":"An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients","officialTitle":"An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2012-04-10","resultsPosted":"2015-05-12","lastUpdate":"2015-05-12"},"enrollment":985,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Moxifloxacin ophthalmic solution, 0.5%","otherNames":["VIGAMOX®"]},{"type":"DRUG","name":"Ofloxacin ophthalmic solution, 0.3%","otherNames":["Tarivid® Eye Drops"]}],"arms":[{"label":"Moxifloxacin","type":"EXPERIMENTAL"},{"label":"Ofloxacin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate Moxifloxacin 0.5% relative to Ofloxacin 0.3% in the treatment of bacterial conjunctivitis in Chinese patients.","primaryOutcome":{"measure":"Clinical Cure Rate","timeFrame":"Day 9","effectByArm":[{"arm":"Moxifloxacin","deltaMin":85.4,"sd":null},{"arm":"Ofloxacin","deltaMin":81.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":489},"commonTop":[]}}